Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of SYH2062 injection in adults with mild to moderate primary hypertension
CTR20262801Phase 2Active
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- Aug 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of syh2062 in essential hypertension, sponsored by CSPC Zhongnuo Pharmaceutical. Started Aug 2026; status: active.
02
Drugs
syh2062
03
Conditions
essential hypertension
Beyond the preview
Go deeper on CTR20262801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262801.